6. INH—100 mg Tablets

7. Morphazinamide—500 mg. Tablets.

8. Prothionamide—125 mg Tablets.

9. Pyrazinamide—500 mg/750 mg. Tablets.

10. Rifampicin—150 mg./300 mg./450 mg. Capsules.

11. Terizidane.

12. Rifampicin—300 mg. + 200 mg.
450 mg. + INH 300 mg.
600 mg. 300 mg.

13. Sodium PAS—834 mg. + INH—25 mg.

14. Thiazetozon 150 mg. + INH 30 mg.

Each vial contains
Streptomycin Sulphate 1 gm. + Sodium methanesulfenate of INH—300 mg.

Shifting of TB drugs from category I to category II of price control order

149. DR. BAPU KALDATE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware of the move to shift certain potent and major TB drugs from category I to category II of Drugs Prices Control Order;

(b) whether it is a fact that as per the Policy decision, all anti-TB drugs have to be included under category I; and

(c) if so, on what basis such a move has been initiated and what is the *locus standi* of the Ministry in this regard?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (c) Anti-TB drugs identified by the Director General of Health Services for the National TB Control Programme were included in Category I of the Drugs Price Control Order, 1987 Government have recommended reclassification of Rifampicin from Category I to Category II, the criterion being the high technology involved in the manufacture of the drug thereby requiring incentives for production.

Budget provision for the purchase of medicine under National Health Programme

150. DR. BAPU KALDATE: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what is the total budget provision for the purchase of medicines required for control of diseases under National Health Programme in 1988-89;

(b) what are the names of the drugs, based on which Government purchased medicines during 1987-88 for these programmes;

(c) whether Government have allocated separate budget for purchase of medicines for each disease;

(d) if so, the details of budget allocated for each during last three years, year-wise;

(e) what are the basis of selection of drugs for each disease and whether any exclusion or inclusion has been done during last two years; and

(f) if so, what are the names of drugs/medicines?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI MOTI LAL VORA): (a) to (f) The